Summit Street Capital Management’s Myriad Genetics MYGN Stock Holding History

Summit Street Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-30,097	Closed	-$875K	–	32
2018 Q4	$875K	Hold	30,097	–	–	0.99%	31
2018 Q3	$1.38M	Hold	30,097	–	–	1.35%	27
2018 Q2	$1.13M	Hold	30,097	–	–	1.09%	30
2018 Q1	$889K	Sell	30,097 -114,000	-79%	-$3.86M	0.88%	31
2017 Q4	$4.95M	Buy	144,097 +6,986	+5%	+$236K	4.88%	2
2017 Q3	$4.96M	Sell	137,111 -20,000	-13%	-$570K	5.67%	2
2017 Q2	$4.06M	Hold	157,111	–	–	4.67%	2
2017 Q1	$3.02M	Buy	157,111 +21,200	+16%	+$376K	3.31%	12
2016 Q4	$2.27M	Buy	135,911 +40,400	+42%	+$731K	2.51%	19
2016 Q3	$1.97M	Buy	+95,511	New	+$2.42M	2.11%	30
2015 Q3	–	Sell	-77,810	Closed	-$2.65M	–	37
2015 Q2	$2.65M	Hold	77,810	–	–	2.54%	19
2015 Q1	$2.75M	Hold	77,810	–	–	2.46%	22
2014 Q4	$2.65M	Buy	+77,810	New	+$2.76M	2.6%	19

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Summit Street Capital Management's MYGN Position: Q1 2019 in Review

Summit Street Capital Management sold out of Myriad Genetics (MYGN) in Q1 2019, closing a stake of 30,097 shares — an estimated $875K sold.

Summit Street Capital Management first reported a position in MYGN in Q4 2014 and held it in 13 quarters. The position peaked at $4.96M in Q3 2017. 262 funds tracked by Wall St. Rank hold MYGN as of Q1 2019.

Summit Street Capital Management reported no remaining Myriad Genetics position as of Q1 2019 after selling out during the quarter.
Summit Street Capital Management sold 30,097 Myriad Genetics shares in Q1 2019, an estimated $875K.
Summit Street Capital Management first reported a position in Myriad Genetics in Q4 2014 and held it in 13 quarters.
Summit Street Capital Management's Myriad Genetics position peaked at $4.96M in Q3 2017.
262 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2019.

Based on Summit Street Capital Management's 13F filing for Q1 2019, filed 15 May 2019.